CA3217734A1 - A novel acylated insulin analog - Google Patents
A novel acylated insulin analog Download PDFInfo
- Publication number
- CA3217734A1 CA3217734A1 CA3217734A CA3217734A CA3217734A1 CA 3217734 A1 CA3217734 A1 CA 3217734A1 CA 3217734 A CA3217734 A CA 3217734A CA 3217734 A CA3217734 A CA 3217734A CA 3217734 A1 CA3217734 A1 CA 3217734A1
- Authority
- CA
- Canada
- Prior art keywords
- insulin analog
- cooh
- human insulin
- lys
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110570030 | 2021-05-24 | ||
| CN202110570030.6 | 2021-05-24 | ||
| PCT/CN2022/094392 WO2022247773A1 (en) | 2021-05-24 | 2022-05-23 | A novel acylated insulin analog |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3217734A1 true CA3217734A1 (en) | 2022-12-01 |
Family
ID=84115321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3217734A Pending CA3217734A1 (en) | 2021-05-24 | 2022-05-23 | A novel acylated insulin analog |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240374692A1 (enExample) |
| EP (1) | EP4347632A4 (enExample) |
| JP (1) | JP2024521757A (enExample) |
| KR (1) | KR20240013778A (enExample) |
| CN (1) | CN115385843A (enExample) |
| AU (1) | AU2022283328A1 (enExample) |
| CA (1) | CA3217734A1 (enExample) |
| WO (1) | WO2022247773A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026517987A (ja) * | 2023-05-24 | 2026-06-02 | ザ ユナイテッド バイオテクノロジー（ヘンチン）シーオー．，エルティーディー． | インスリン誘導体およびその使用 |
| WO2025098457A1 (zh) * | 2023-11-07 | 2025-05-15 | 甘李药业股份有限公司 | 用于降糖的酰化胰岛素 |
| CN122555570A (zh) * | 2023-11-08 | 2026-08-11 | 甘李药业股份有限公司 | 包含胰岛素衍生物的药物组合物的治疗用途 |
| CN117756914B (zh) * | 2023-12-15 | 2024-09-03 | 瀚晖制药有限公司 | 依柯胰岛素的制备方法 |
| CN118063589A (zh) * | 2024-02-04 | 2024-05-24 | 乐普健糖药业(重庆)有限公司 | 一种超长效胰岛素类似物及其制备方法和用途 |
| WO2025228255A1 (zh) * | 2024-04-28 | 2025-11-06 | 正大天晴药业集团股份有限公司 | 酰化人胰岛素类似物 |
| WO2026109062A1 (zh) * | 2024-11-25 | 2026-05-28 | 甘李药业股份有限公司 | 含酰化胰岛素的药物组合物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1888104A2 (en) * | 2005-05-26 | 2008-02-20 | Novo Nordisk A/S | Acylated insulin with high purity |
| WO2007104737A1 (en) * | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
| CN101437849B (zh) * | 2006-05-09 | 2015-09-30 | 诺沃-诺迪斯克有限公司 | 胰岛素衍生物 |
| AU2008288413B2 (en) * | 2007-08-15 | 2013-09-26 | Novo Nordisk A/S | Insulin analogues with an acyl and aklylene glycol moiety |
| HUE032284T2 (en) * | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
| CN102149411A (zh) * | 2008-09-12 | 2011-08-10 | 诺沃—诺迪斯克有限公司 | 酰化肽或蛋白的方法 |
| CN104788556A (zh) * | 2011-12-15 | 2015-07-22 | 上海恒瑞医药有限公司 | 人胰岛素类似物及其酰化衍生物 |
| WO2014009316A1 (en) * | 2012-07-09 | 2014-01-16 | Novo Nordisk A/S | Novel use of insulin derivatives |
| CA2926701A1 (en) | 2013-10-07 | 2015-04-16 | Novo Nordisk A/S | Novel derivative of an insulin analogue |
| AR099569A1 (es) * | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| US9856292B2 (en) * | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| EP3341401A1 (en) * | 2015-08-25 | 2018-07-04 | Novo Nordisk A/S | Novel insulin derivatives and the medical uses hereof |
| BR112018002416A2 (pt) * | 2015-08-25 | 2018-09-18 | Novo Nordisk As | derivados de insulina e seus usos médicos |
| US10815287B2 (en) | 2016-08-02 | 2020-10-27 | Jiangsu Hengrui Medicine Co., Ltd. | Acylated derivative of human insulin or analogue thereof |
| WO2019149245A1 (zh) * | 2018-02-01 | 2019-08-08 | 江苏恒瑞医药股份有限公司 | 含人胰岛素类似物的酰化衍生物的药物组合物及其制备方法 |
| BR112022013009A2 (pt) * | 2019-12-30 | 2022-09-06 | Gan & Lee Pharmaceuticals Co Ltd | Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina |
| JP2020117542A (ja) * | 2020-05-07 | 2020-08-06 | ノヴォ ノルディスク アー／エス | 錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物 |
-
2022
- 2022-05-23 CA CA3217734A patent/CA3217734A1/en active Pending
- 2022-05-23 AU AU2022283328A patent/AU2022283328A1/en active Pending
- 2022-05-23 CN CN202210567043.2A patent/CN115385843A/zh active Pending
- 2022-05-23 US US18/563,090 patent/US20240374692A1/en active Pending
- 2022-05-23 JP JP2023572618A patent/JP2024521757A/ja active Pending
- 2022-05-23 KR KR1020237044398A patent/KR20240013778A/ko active Pending
- 2022-05-23 WO PCT/CN2022/094392 patent/WO2022247773A1/en not_active Ceased
- 2022-05-23 EP EP22810498.0A patent/EP4347632A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240013778A (ko) | 2024-01-30 |
| CN115385843A (zh) | 2022-11-25 |
| JP2024521757A (ja) | 2024-06-04 |
| US20240374692A1 (en) | 2024-11-14 |
| WO2022247773A1 (en) | 2022-12-01 |
| AU2022283328A1 (en) | 2023-11-16 |
| EP4347632A1 (en) | 2024-04-10 |
| EP4347632A4 (en) | 2025-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022247773A1 (en) | A novel acylated insulin analog | |
| JP6121992B2 (ja) | ポリペプチド | |
| AU2008288413B2 (en) | Insulin analogues with an acyl and aklylene glycol moiety | |
| ES2369895T3 (es) | Insulina monocatenaria. | |
| DK172211B1 (da) | Basisk modificeret insulin-derivat | |
| US20090069216A1 (en) | Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof | |
| RU2684456C2 (ru) | Новые производные инсулина и их применение в медицине | |
| CN114478747B (zh) | 一种人胰岛素或其类似物的酰化衍生物 | |
| US20150119320A1 (en) | Pegylated oxm variants | |
| MX2012014641A (es) | Derivados de insulina que contienen enlaces disulfuro adicionales. | |
| EP4079757A1 (en) | Acylated oxyntomodulin peptide analog | |
| JP2013540771A (ja) | 新規ｎ末端修飾インスリン誘導体 | |
| CA3071686A1 (en) | Novel acylated insulin analogues and uses thereof | |
| JP2022543586A (ja) | グルコース調節型立体配座スイッチを有するインスリン類似体 | |
| KR20250017252A (ko) | 인간 아밀린 유사체 및 이의 유도체 및 이의 용도 | |
| CN119343368A (zh) | 一种人胰淀素多肽衍生物及其用途 | |
| US20140357838A1 (en) | N-Terminally Modified Insulin Derivatives | |
| CN106554404B (zh) | 艾塞那肽修饰物及其用途 | |
| EP2293811A1 (en) | Derivatised hybrid peptides of amylin and salmon calcitonin | |
| CN113811614A (zh) | 多肽衍生物及其制备方法 | |
| JP2008546816A (ja) | エキセンディン４ポリペプチドフラグメントおよびその使用 | |
| CN103379919A (zh) | 瘦蛋白衍生物 | |
| CN111234000A (zh) | 艾塞纳肽类似物 | |
| ES2772223T3 (es) | Polipeptidos | |
| CN111909255A (zh) | 胰岛素衍生物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250324 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250324 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250324 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260119 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260119 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260224 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260224 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260225 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260330 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260330 |